Canwe predict which patient will fail drug treatment for overactive bladder? a think tank discussion

Neurourology and Urodynamics

Volumn 29, Issue 4, 2010, Pages 652-657

  Nitti, Victor W ^a   Kopp, Zoe ^b   Lin, Alex T L ^c   Moore, Kate H ^d   Oefelein, Michael ^e   Mills, Ian W ^f  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b PFIZER INC   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d ST GEORGE HOSPITAL   (Australia)

^e ALLERGAN INC   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

OAB; Outcomes; Phramacotherapy

Indexed keywords

BOTULINUM TOXIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TOLTERODINE;

BEHAVIOR THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; DAILY LIFE ACTIVITY; DIAGNOSTIC ERROR; DRUG METABOLISM; HUMAN; MIXED INCONTINENCE; NEUROMODULATION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHYSIOTHERAPY; PREDICTION; QUALITY OF LIFE; REVIEW; STRESS; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY URGENCY; URODYNAMICS; STRESS INCONTINENCE; URGE INCONTINENCE;

BEHAVIOR THERAPY; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; MUSCARINIC ANTAGONISTS; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, STRESS; URINARY INCONTINENCE, URGE;

EID: 77953590530     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20910     Document Type: Review

References (51)

1. Krowinski W, Steiber S. Measuring patient satisfaction, 2nd edition. Chicago: American Hospital Publishing; 1996. p.15.
2. Weaver M, Patrick DL, Markson LE, et al. Issues in the measurement of satisfaction with treatment. AmJ Manag Care 1997;3:579-594
3. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996;334: 1441-1447
4. In: Cousins M,Wall PD, Melzack R, editors. Textbook of pain: Acute and postoperative pain, 3rd edition. Philadelphia: Churchill Livingstone; 1994.
5. Kehlet H. The importance of post operative pain relief. Acta Anaesthesiol Scand 2002;37:122-123
6. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain. J AmMed Assoc 1995;274:1874-1880
7. McCracken L, Klock A, Mingay D. Assessment of satisfactionwith treatment for chronic pain. J Pain Symptom Manage 1997;14:292-299
8. Pleil AM, Coyne KS, Rewe PR. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-TheBSW.Value Health 2005;8:S25-34.
9. Atkinson M, Sinha A, Hass S, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:1-13.
10. Atkinson M, Kumar R, Cappelleri J, et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005;8:S9-24.
11. Piault E, Marcucci G, Kopp Z, et al. Patient satisfaction: International development, translatability assessment and linguistic validation of the OAB-S, an overactive bladder treatment satisfaction questionnaire. ISPOR 8th Annual European Congress. Florence, Italy. Value Health 2005;8:A88.
12. PiaultE, Evans CJ, Espindle D, etal. Developmentand validation of the overactive bladder satisfaction (OAB-S) questionnaire. Neurourol Urodyn 2008;27:179-190
13. Conway K, Uzun V, Kopp Z, et al. Linguistic validation of the overactive bladder questionnaire (OAB-q), OAB-q SF and the overactive bladder-validated 8 (OAB V8) screening questionnaire for this condition in Europe, Asia, North America, and South America. 30th Annual Meeting of the International Urogynecological Association (IUGA). Copenhagen, Denmark. Int Urogynecol J 2005;16: S103-4.
14. Kiresuk T, Sherman R. Goal attainment scaling: A general method of evaluating comprehensive community mental health programs.Community Ment Health J 1968;4:443-453
15. Rockwood K, Stolee P, Howard K, et al. Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology 1996;15:330-338
16. Rockwood K, Song F, GormanM. Attainment of treatment goals by peoplewith Alzheimer's disease receiving galantamine: A randomized controlled trial. Can Med Assoc J 2006;174:1099-1105
17. Rockwood K, Stolee P, Fox R. The use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol 1993;46: 113-118
18. Brubaker L, Kopp Z, PiaultE, etal. Developmentof a Self-AssessmentGoal Achievement (SAGA) Questionnaire in urinary disorders. Presented at: International Continence Society; August 20-24, 2007; Rotterdam, the Netherlands.
19. Kuo H-C. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003;170:835-839
20. Kuo HX, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: A randomized double blind placebo controlled study. J Urol 2006;176: 641-645
21. Natalin R, Reis LO, Alpendre C, et al. Triple therapy in refractory detrusor overactivity: A preliminary study. World J Urol 2010;28:75-81. 1007/s00345- 009-0400-406
22. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and Botulinum A injection. J Urol 2008;180:217-222
23. Moore KH, Nickson P, Richmond DH, etal. Detrusor mastcells in refractory idiopathic instability. Br J Urol 1992;70:17-21.
24. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst 2009; Rev(1):MR000006.
25. Michel MC, de la Rosette JJ, Piro M, et al. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 2004;172:601-604
26. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505.
27. Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: Effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008;102:1133-1139
28. Starkman JS, Duffy JW III, Wolter CE, et al. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: Management with sacral neuromodulation. IntUrogyneco l J Pelvic Floor Dysfunct2008;19:277-282
29. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic reviewand meta-analysis. Eur Urol 2008;54:543-562
30. RosenbergMT, Newman DK, Tallman CT, et al. Overactive bladder: Recognition requires vigilance for symptoms. Cleve Clin J Med 2007;74:S21-9.
31. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospiumchloride. Clin Pharmacokinet2005;44:701-720
32. Nijman RJ, Borgstein NG, Ellsworth P, et al. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: Results from 2 randomized, placebo controlled trials. J Urol 2005;173:1334-1339
33. Goldstein DB, Need AC, Singh R, et al. Potential genetic causes of heterogeneity of treatment effects. Am J Med 2007;120:S21-5.
34. Kuipers M, Smulders R, Krauwinkel W, et al. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci 2006;102:405-412
35. Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol 2009;65:551-560
36. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006;45:325-350.
37. SwartP J, Krauwinkel WJ, Smulders RA, etal. Pharmacokinetic effectof ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006;99:33-36
38. Burgio KL. Behavioral treatment options for urinary incontinence. Gastroenterology 2004;126:S82-9.
39. Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in olderwomen: A randomized controlled trial. JAMA 2002;288:2293-2299
40. Milne JL. Behavioral therapies for overactive bladder: Making sense of the evidence. JWound Ostomy Continence Nurs 2008;35:93-101.
41. Wyman JF, Fantl JA, McClish DK, et al. Comparative efficacy of behavioral interventions in themanagement of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 1998;179:999-1007.
42. Mattiasson A, Blaakaer J, Hoye K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003;91:54-60.
43. Herschorn S, Becker D, Miller E, et al. Impact of a health education intervention in overactive bladder patients. Can J Urol 2004;11:2430-2437
44. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J AmGeriatr Soc 2000;48:370-374
45. Klutke CG, Burgio KL,Wyman JF, et al. Combined effects of behavioral interventionandtolterodine in patientsdissatisfied with overactivebladder medication. J Urol 2009;181:2599-2607
46. Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release. IntJ Clin Pract2009;63:973-976
47. Wein AJ, Khullar V, Wang JT, et al. Achieving continence with antimuscarinic therapy for overactive bladder: Effects of baseline incontinence severity and bladder diary duration. BJU Int 2007;99:360-363
48. Kreder KJ, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 2003;92:418-421
49. Khullar V, Hill S, Laval KU, etal. Treatmentof urge-predominantmixed urinary incontinence with tolterodine extended release: A randomized, placebocontrolled trial. Urology 2004;64:269-274
50. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patientswith overactive bladder symptoms treated with solifenacin. BJU Int 2005;95:81-85
51. BentAE, Gousse AE, Hendrix SL, etal. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. Neurourol Urodyn 2008;27:212-221